Your browser doesn't support javascript.
loading
Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study.
Mita, Tomoya; Katakami, Naoto; Yoshii, Hidenori; Onuma, Tomio; Kaneto, Hideaki; Osonoi, Takeshi; Shiraiwa, Toshihiko; Yasuda, Tetsuyuki; Umayahara, Yutaka; Yamamoto, Tsunehiko; Yokoyama, Hiroki; Kuribayashi, Nobuichi; Jinnouchi, Hideaki; Gosho, Masahiko; Shimomura, Iichiro; Watada, Hirotaka.
Afiliación
  • Mita T; Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan. tom-m@juntendo.ac.jp.
  • Katakami N; Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Yoshii H; Department of Medicine, Diabetology and Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, Shinsuna 3-3-20, Koto-Ku, Tokyo, 136-0075, Japan.
  • Onuma T; Department of Medicine, Diabetology and Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, Shinsuna 3-3-20, Koto-Ku, Tokyo, 136-0075, Japan.
  • Kaneto H; Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
  • Osonoi T; Naka Kinen Clinic, 745-5, Nakadai, Naka City, Ibaraki, 311-0113, Japan.
  • Shiraiwa T; Shiraiwa Medical Clinic, 1-12-8 Hirano, Kashiwara, Osaka, 582-0019, Japan.
  • Yasuda T; Osaka Police Hospital, 10-31 Kitayamacho, Tennoji-Ku, Osaka, 543-0035, Japan.
  • Umayahara Y; Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi-Ku, Osaka, 558-8558, Japan.
  • Yamamoto T; Kansai Rosai Hospital, 3-1-69 Inabasou, Amagasaki-Shi, Hyogo, 660-8511, Japan.
  • Yokoyama H; Jiyugaoka Medical Clinic, Internal Medicine, West 6, South 6-4-3, Obihiro, Hokkaido, 080-0016, Japan.
  • Kuribayashi N; Misaki Naika Clinic, 6-44-9 Futawahigashi, Funabashi, Chiba, 274-0805, Japan.
  • Jinnouchi H; Jinnouchi Hospital, Kuhonji 6-Chome 2-3, Kumamoto, 862-0976, Japan.
  • Gosho M; Department of Biostatistics, Institute of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
  • Shimomura I; Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Watada H; Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Sci Rep ; 13(1): 14649, 2023 09 05.
Article en En | MEDLINE | ID: mdl-37669959
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Aterosclerosis / Inhibidores de la Dipeptidil-Peptidasa IV / Infarto del Miocardio Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Aterosclerosis / Inhibidores de la Dipeptidil-Peptidasa IV / Infarto del Miocardio Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article